Navigation Links
Erlotinib improves progression-free survival as first-line therapy in advanced lung cancer
Date:10/9/2010

For patients with advanced lung cancer whose tumors carry EGFR activating mutations, first-line treatment with erlotinib nearly tripled progression-free survival compared to a standard chemotherapy combination, show results from the first prospective Phase-III study to report findings in this setting.

The new results from the OPTIMAL trial were reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy.

"Erlotinib is very effective and well tolerated in advanced NSCLC patients who harbor EGFR activating mutations. It is 2 to 3 times more effective than doublet chemotherapy," said study leader Professor Caicun Zhou of Shanghai Pulmonary Hospital, Tongji University, China.

The OPTIMAL study included 165 patients whose lung cancer carried mutations activating the Epithelial Growth Factor Receptor (EGFR). Participants had not received systemic treatment for their cancer.

Of these patients, 83 were randomly assigned to receive erlotinib 150 mg/day, and 82 patients were assigned to receive a 'doublet' combination chemotherapy of gemcitabine and carboplatin. The primary endpoint of the study was progression-free survival.

In his presentation at the ESMO Congress, Prof Zhou reported that the median progression-free survival in the erlotinib arm was 13.1 months, compared to 4.6 months for the chemotherapy arm of the study. The objective response rate with erlotinib was 83%, compared to 36% for gemcitabine plus carboplatin. 31 patients in the erlotinib arm are still under study and progression free compared to only 1 in the chemotherapy arm.

"OPTIMAL is the first reported prospective Phase-III study to confirm the role of erlotinib in advanced NSCLC patients with EGFR activating mutations," Prof Zhou said. "It does much better than the standard doublet chemotherapy and so we should start erlotinib treatment as soon as possible after the diagnosis of advanced NSCLC with EGFR activating mutations," he added.

Safety analyses showed lower rates of adverse events with erlotinib than with chemotherapy, the researchers report.

Also at the ESMO Congress, Professor Yi-long Wu from Guangdong General Hospital (GGH) & Guangdong Academy of Medical Sciences in China reported the first biomarker results from the study. This analysis aimed to evaluate the impact on various biomarkers with survival among the patient population.

"Detailed biomarker analysis did not identify additional markers that could be used to further optimize treatment decisions. It was found that patients who had exon 19 deletions in EGFR had longer progression-free survival with erlotinib than those with L858R mutations and only one patient had an EGFR T790M mutation, and remained progression-free for only 0.62 months," Prof Wu said.

The results of the OPTIMAL trial have implications for clinical practice, commented Dr Federico Cappuzzo, Director of Medical Oncology at Ospedale Civile in Livorno, Italy.

"These data, combined with data coming from another four large Phase-III studies comparing chemotherapy versus gefitinib, another orally available EGFR tyrosine kinase inhibitor (EGFR-TKI), confirmed that erlotinib or gefitinib represent the best therapeutical option we can offer today as front-line therapy in metastatic NSCLC with activating EGFR mutations."

Dr Cappuzzo noted that all studies so far in this setting have been conducted in Asian populations. A confirmatory study in Caucasian patients is currently ongoing.


'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Related biology news :

1. For insulin sensitive overweight patients, 1 session of exercise improves metabolic health
2. Microarray analysis improves prenatal diagnosis
3. Replacing corn with perennial grasses improves carbon footprint of biofuels
4. Study finds rescue course of antenatal steroids improves outcome in premature babies
5. Queens University Belfast improves Malaysian public health
6. Taste, odor intervention improves cancer therapy, according to Virginia Tech, Wake Forest study
7. New, less invasive genetic test greatly improves pregnancy rates in older women with poor prognosis
8. Army study improves ability to predict drinking water needs
9. Technology improves salmon passage at hydropower dams
10. Water quality improves after lawn fertilizer ban, study shows
11. U-Iowa improves delivery of cancer-fighting molecules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2016)... , Dec. 14, 2016 "Increase in ... biometrics market" The mobile biometrics market is expected to ... 49.33 billion by 2022, at a CAGR of 29.3% ... factors such as the growing demand for smart devices, ... transactions. "Software component is expected to grow ...
(Date:12/8/2016)... Dec. 8, 2016  Singulex, Inc., the leader in ... entered into a license and supply agreement with Thermo ... agreement provides Singulex access to Thermo Scientific BRAHMS PCT ... is used to diagnose systemic bacterial infection and ... to aid in assessing the risk of critically ...
(Date:12/7/2016)... , Dec. 7, 2016   Avanade ... successful Formula One teams in history, exploit biometric data ... stop performance and maintain the competitive edge against their ... 2016. Avanade has worked with Williams ... range of biometric data (heart rate, breathing rate, temperature ...
Breaking Biology News(10 mins):
(Date:1/20/2017)... January 20, 2017 Stock-Callers.com explores ... have influenced the most recent performances of select equities. ... RGLS ), Abeona Therapeutics Inc. (NASDAQ: ... TBPH ), and Sage Therapeutics Inc. (NASDAQ: ... Grand View Research, global Biotech market size is expected to reach $604.40 ...
(Date:1/20/2017)... 2017 http://www.Financialbuzz.com - ... leading causes of death worldwide. There were 8.2 million ... cancer related deaths increased gradually over time, the death ... of various cancers continues to drive demand of biological ... Global Market Insights, Inc. cancer biological therapy market size was ...
(Date:1/19/2017)... 2017 Research and Markets has announced the ... Cancer Type, Application - Global Opportunity Analysis and Industry Forecast, 2014-2022" ... ... market is projected to reach $15,737 million by 2022 from $6,521 ... 2022. Omic technologies segment accounted for more than ...
(Date:1/19/2017)... and HOUSTON , Jan. 19, ... today announced the formation of its Medical/Clinical Advisory ... and industry veterans who enhance the range and ... accelerates development of its novel prenatal diagnostic tests.  ... clinical and strategic guidance for the company,s product ...
Breaking Biology Technology: